Setterwalls represented Abboxia in the dispute. In April 2019 the Medical Products Agency decided to reject Abboxias’ application for marketing authorisation for parallel import of pharmaceuticals…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
